Floatz logo

Shr-A1904

Pancreatic Cancer

Fudan UniversityPhase 2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
59/ 100

Competitive context

381 Active assets in the Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Shr-A1904 is also rated in:

CLDN18.2-positive Advanced Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
malignant pancreatic neoplasmDormant
CC
Indicative ·
41 / 100
View asset →
Advanced Solid CancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →